Company research
Applied Therapeutics, Inc.
CIK 1697532Updated Nov 16, 2026
Historical securities (1)
APLT · NASDAQ · equity · closed Feb 3, 2026APLT price & chart
This listing closed Feb 3, 2026. Live provider charts are shown only for current listings.
About the company
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG).
Financials
FY 2024 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q2 2023 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 34,374,000Source | 106,566,000Source | 45,195,000Source | 37,342,000Source | 127,778,000Source | 43,646,000Source | 56,907,000Source | 151,234,000Source | 86,691,000Source | 54,833,000Source | 38,363,000Source | 89,892,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,945,000Source | 98,867,000Source | 37,457,000Source | 30,421,000Source | 122,197,000Source | 35,616,000Source | 50,762,000Source | 146,484,000Source | 79,398,000Source | 49,898,000Source | 16,657,000Source | 53,888,000Source |
| Assets, CurrentUSD | 31,654,000Source | 104,603,000Source | 44,488,000Source | 34,511,000Source | 127,572,000Source | 42,821,000Source | 53,966,000Source | 150,906,000Source | 83,646,000Source | 54,386,000Source | 37,308,000Source | 88,394,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 19,709,000Source | 5,483,000Source | 7,031,000Source | 4,090,000Source | 5,122,000Source | 7,205,000Source | 3,204,000Source | 4,169,000Source | 4,248,000Source | 4,234,000Source | 6,728,000Source | 7,571,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,468,000Source | 1,963,000Source | 510,000Source | 2,579,000Source | 206,000Source | 628,000Source | 2,688,000Source | 328,000Source | 2,792,000Source | 447,000Source | 857,000Source | 1,298,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 34,935,000Source | 100,674,000Source | 56,239,000Source | 19,904,000Source | 55,386,000Source | 47,980,000Source | 20,239,000Source | 83,940,000Source | 29,685,000Source | 71,979,000Source | 34,302,000Source | 27,353,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 35,000Source | 11,000Source | 7,000Source | 35,000Source | 11,000Source | 6,000Source | 35,000Source | 11,000Source | 35,000Source | 8,000Source | 5,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 635,759,000Source | 624,098,000Source | 419,856,000Source | 634,768,000Source | 622,007,000Source | 384,197,000Source | 632,668,000Source | 619,807,000Source | 631,181,000Source | 451,432,000Source | 352,828,000Source | 328,958,000Source |
| Retained Earnings (Accumulated Deficit)USD | -636,355,000Source | -618,217,000Source | -430,907,000Source | -617,365,000Source | -549,626,000Source | -388,537,000Source | -596,035,000Source | -552,524,000Source | -574,210,000Source | -468,586,000Source | -348,823,000Source | -266,315,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | — | — | — | 51,000Source | -107,000Source |
| Stockholders' Equity Attributable to ParentUSD | -561,000Source | 5,892,000Source | -11,044,000Source | 17,438,000Source | 72,392,000Source | -4,334,000Source | 36,668,000Source | 67,294,000Source | 57,006,000Source | -17,146,000Source | 4,061,000Source | 62,539,000Source |
| Liabilities and EquityUSD | 34,374,000Source | 106,566,000Source | 45,195,000Source | 37,342,000Source | 127,778,000Source | 43,646,000Source | 56,907,000Source | 151,234,000Source | 86,691,000Source | 54,833,000Source | 38,363,000Source | 89,892,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 32,902,000Source | 98,967,000Source | 55,504,000Source | 17,749,000Source | 55,356,000Source | 47,188,000Source | 17,965,000Source | 83,905,000Source | 27,296,000Source | 71,182,000Source | 33,424,000Source | 26,462,000Source |
| Operating Lease, Liability, CurrentUSD | 467,000Source | 264,000Source | 491,000Source | 447,000Source | 185,000Source | 486,000Source | 426,000Source | 308,000Source | 406,000Source | 429,000Source | 477,000Source | 442,000Source |
| Accounts Payable, CurrentUSD | 4,800,000Source | 2,837,000Source | 6,005,000Source | 4,861,000Source | 2,683,000Source | 4,687,000Source | 4,868,000Source | 4,019,000Source | 4,433,000Source | 1,742,000Source | 4,534,000Source | 9,461,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,033,000Source | 1,707,000Source | 44,000Source | 2,155,000Source | 30,000Source | 170,000Source | 2,274,000Source | 35,000Source | 2,389,000Source | 38,000Source | 414,000Source | 891,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 30,600,000Source | 80,800,000Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 13,923,000Source | 26,935,000Source |
cash flow · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -21,825,000Source | -83,938,000Source | -105,624,000Source | -119,763,000Source | -82,508,000Source | -105,584,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,487,000Source | 2,379,000Source | 13,467,000Source | 7,360,000Source | 9,162,000Source | 11,177,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 435,000Source | 527,000Source | 2,691,000Source | -2,792,000Source | -4,927,000Source | 8,821,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -28,636,000Source | -18,911,000Source | -84,305,000Source | -55,173,000Source | -78,093,000Source | -90,728,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | — | — | 13,872,000Source | 13,170,000Source | 12,433,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 0Source | 115,497,000Source | 113,805,000Source | 74,542,000Source | 27,692,000Source | 74,717,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -28,636,000Source | 96,586,000Source | 29,500,000Source | 33,241,000Source | -37,231,000Source | -3,578,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 11,945,000Source | 98,867,000Source | 30,421,000Source | 122,197,000Source | 50,762,000Source | 146,484,000Source | 79,398,000Source | 49,898,000Source | 16,657,000Source | 53,888,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,141,000Source | 2,091,000Source | 2,100,000Source | 1,890,000Source | 1,487,000Source | 2,379,000Source | 15,567,000Source | 7,360,000Source | 9,162,000Source | 11,177,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 30,600,000Source | 80,800,000Source |
| General and Administrative ExpenseUSD | — | — | 8,157,000Source | 15,037,000Source | 13,175,000Source | 10,580,000Source | 17,688,000Source | 9,066,000Source | 56,010,000Source | 20,623,000Source | 27,316,000Source | 43,048,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | -51,000Source | 158,000Source | 5,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,990,000Source | -68,591,000Source | -21,330,000Source | 2,898,000Source | -21,825,000Source | -83,938,000Source | -105,624,000Source | -119,763,000Source | -82,508,000Source | -105,584,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | 2,898,000Source | — | -83,938,000Source | — | -119,763,000Source | -82,508,000Source | -105,584,000Source |
| Nonoperating Income (Expense)USD | — | — | -2,232,000Source | -38,848,000Source | 1,768,000Source | 23,338,000Source | 3,700,000Source | -62,845,000Source | -1,325,000Source | -55,228,000Source | 442,000Source | 34,000Source |
| Operating ExpensesUSD | — | — | 17,758,000Source | 29,865,000Source | 23,098,000Source | 20,584,000Source | 25,525,000Source | 21,283,000Source | 104,754,000Source | 74,528,000Source | 82,950,000Source | 105,618,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -7,000Source | -21,000Source | -33,000Source | -34,000Source | -25,000Source | -26,000Source | -77,000Source | -27,000Source | -177,000Source | -521,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | — | 8,928,000Source | 77,388,000Source | 128,484,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 0Source | 33,000Source | 343,000Source | 90,000Source | 49,000Source | 511,000Source |
income statement · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,000,000Source | 122,000Source | 0Source | 144,000Source | 0Source | 190,000Source | 455,000Source | 9,993,000Source | — | — |
| Operating Income (Loss)USD | — | — | -16,758,000Source | -29,743,000Source | -23,098,000Source | -20,440,000Source | -25,525,000Source | -21,093,000Source | -104,299,000Source | -64,535,000Source | -82,950,000Source | -105,618,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -7,000Source | -21,000Source | -33,000Source | -34,000Source | -25,000Source | -26,000Source | -77,000Source | -27,000Source | -177,000Source | -521,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,990,000Source | -68,591,000Source | -21,330,000Source | 2,898,000Source | -21,825,000Source | -83,938,000Source | -105,624,000Source | -119,763,000Source | -82,508,000Source | -105,584,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.13Source | -0.48Source | -0.15Source | 0.02Source | -0.15Source | -0.67Source | -0.76Source | -1.42Source | -2.18Source | -4.12Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.13Source | -0.48Source | -0.15Source | -0.13Source | -0.15Source | -0.67Source | -0.76Source | -1.42Source | -2.18Source | -4.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 145,559,604Source | 144,345,781Source | 145,091,474Source | 143,934,239Source | 144,787,971Source | 125,318,993Source | 139,534,746Source | 84,244,494Source | 37,825,431Source | 25,598,181Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 145,559,604Source | 144,345,781Source | 145,091,474Source | 152,392,748Source | 144,787,971Source | 125,318,993Source | 139,534,746Source | 84,244,494Source | 37,825,431Source | 25,598,181Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 8,157,000Source | 15,037,000Source | 13,175,000Source | 10,580,000Source | 17,688,000Source | 9,066,000Source | 56,010,000Source | 20,623,000Source | 27,316,000Source | 43,048,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 144,000Source | 1,357,000Source | 364,000Source | 628,000Source | 621,000Source | 586,000Source | 3,534,000Source | 1,372,000Source | 685,000Source | 555,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | 2,898,000Source | — | -83,938,000Source | — | -119,763,000Source | -82,508,000Source | -105,584,000Source |
| Nonoperating Income (Expense)USD | — | — | -2,232,000Source | -38,848,000Source | 1,768,000Source | 23,338,000Source | 3,700,000Source | -62,845,000Source | -1,325,000Source | -55,228,000Source | 442,000Source | 34,000Source |
| Operating ExpensesUSD | — | — | 17,758,000Source | 29,865,000Source | 23,098,000Source | 20,584,000Source | 25,525,000Source | 21,283,000Source | 104,754,000Source | 74,528,000Source | 82,950,000Source | 105,618,000Source |
| Research and Development ExpenseUSD | — | — | 9,601,000Source | 14,828,000Source | 9,923,000Source | 10,004,000Source | 7,837,000Source | 12,217,000Source | 48,744,000Source | 53,905,000Source | 55,634,000Source | 62,570,000Source |
Offerings
Registration 333-271887
Registration 333-278182
Filing attachments
d41524dex991.htm · 8-K · 2025-12-12
EX-99.1 5 d41524dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 December 11, 2025 For Release: Immediately Cycle Pharmaceuticals to Acquire Applied Therapeutics Applied Therapeutic’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases NEW YORK, Dec. 11, 2025 - Applied Therapeutics, Inc. (Nasdaq: APLT; “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative tr…
Read attachment ↗aplt-ex99_1.htm · 8-K · 2025-11-20
EX-99.1 2 aplt-ex99_1.htm EX-99.1 EX-99.1 Applied Therapeutics Announces Corporate Updates NEW YORK, November 20, 2025 - Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced that Applied Therapeutics’ Board of Directors (the “Board”) has initiated a process to explore strategic alternatives for the Company. The Board intends to evaluate a broad range of oppor…
Read attachment ↗aplt-ex99_1.htm · 8-K · 2025-11-13
EX-99.1 2 aplt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Applied Therapeutics Reports Third Quarter 2025 Financial Results - Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes - Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treatment of Classic Galactosemia - New data on govorestat for the treatment of PMM2-CDG published in JIMD and presented at the 2025 ASHG Annual Meeting - Announces Board of …
Read attachment ↗aplt-ex99_1.htm · 8-K · 2025-08-13
EX-99.1 2 aplt-ex99_1.htm EX-99.1 EX-99.1 Applied Therapeutics Reports Second Quarter 2025 Financial Results - CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE Phase 2/3 trial of govorestat for the treatment of CMT-SORD at PNS 2025 Annual Meeting highlighting slowed progression of disease observed via MRI at 24 months - Launched new sponsore…
Read attachment ↗aplt-ex99_1.htm · 8-K · 2025-06-17
EX-99.1 2 aplt-ex99_1.htm EX-99.1 EX-99.1 Applied Therapeutics Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 212.220.9319 www.appliedtherapeutics.com CONFIDENTIAL June 13, 2025 Riccardo Perfetti Dear Riccardo: This letter agreement (this “Agreement”) confirms our agreement regarding the terms of your separation from employment with Applied Therapeutics, Inc. (the “Company”). The Company and you are hereinafter referred to together as the “Parties” and each as a…
Read attachment ↗aplt-ex99_2.htm · 8-K · 2025-06-17
EX-99.2 3 aplt-ex99_2.htm EX-99.2 EX-99.2 APPLIED THERAPEUTICS INC. Evan Bailey, MD June 13, 2025 Dear Evan: This Amended and Restated Offer Letter (the “Letter Agreement”) confirms the terms and conditions of your employment at Applied Therapeutics Inc. (the “Company”) effective June 15, 2025 (the “Effective Date”). This Letter Agreement amends, restates, and supersedes the offer letter between you and the Company signed on March 15, 2021 (the “Prior Offer Letter”). With those understa…
Read attachment ↗